Astrana Health (NASDAQ:ASTH) Price Target Cut to $49.00 by Analysts at Bank of America

Astrana Health (NASDAQ:ASTH) had its price objective lowered by Bank of America from $55.00 to $49.00 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts also recently commented on ASTH. Macquarie raised Astrana Health to a “hold” rating in a research note on Monday, December 16th. Truist Financial cut their price target on Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, January 13th. Robert W. Baird lowered their price objective on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research report on Monday. Finally, Stifel Nicolaus cut their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Astrana Health presently has an average rating of “Moderate Buy” and a consensus target price of $56.83.

Astrana Health Stock Performance

Shares of Astrana Health stock opened at $27.21 on Tuesday. The firm’s fifty day simple moving average is $34.44 and its 200-day simple moving average is $44.05. Astrana Health has a 12 month low of $23.12 and a 12 month high of $63.20. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of 20.93, a PEG ratio of 1.37 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. As a group, equities analysts forecast that Astrana Health will post 1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC purchased a new stake in shares of Astrana Health during the 3rd quarter worth $35,000. New York State Teachers Retirement System acquired a new stake in shares of Astrana Health in the third quarter valued at about $2,515,000. QRG Capital Management Inc. purchased a new stake in Astrana Health during the third quarter worth about $355,000. Moloney Securities Asset Management LLC acquired a new position in Astrana Health during the third quarter worth about $1,089,000. Finally, Amalgamated Bank purchased a new position in Astrana Health in the third quarter valued at about $713,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.